Sony Salzman
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
Latest by Sony Salzman
Do Intimate Relationships Affect Drug Use in Black Gay and Bisexual Men?
Men with a main partner used drugs during sex at similar rates to those with only casual partners. But studying couples could lead to HIV prevention programs that could reduce racial disparity.
The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
When Providers Don't Use Gender-Affirming Language, It Negatively Impacts HIV-Positive Transgender Women's Health
A new study shows that helping clinicians use gender-affirming language is important for transgender women in care. But we need more research on how HIV medications and feminizing hormones interact.
NIH, Gates Foundation Hatch Plan to Develop Affordable Gene Therapy for HIV, Sickle Cell Disease
The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.
Two-Drug Regimen Is Being Studied as a Long-Acting Injectable. But Does It Work as a Daily Pill?
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated
"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.
Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work.
Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.
Getting Hepatitis C Treatment to People in Jails Isn’t Easy. Here Are Some Recommendations.
People in jail, who are often in the system for less time than those in prison, often receive little to no hepatitis C screening or treatment. One provider works to change this in Massachusetts.
One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.